Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has The Minimal Residual Disease Market Size Shifted, And What Is the Outlook Through 2034?

The market size for minimal residual disease has seen a quick expansion in the past few years. It’s projected to surge from $1.78 billion in 2024 to $2.01 billion in 2025, with a compound annual growth rate (CAGR) of 12.6%. Factors contributing to the growth during this historic period include an uptick in the incidence of cancer, increased spending on research and development, accessibility of affordable healthcare, a rise in blood cancer rates, and heightened public awareness.

The market for minimal residual disease is poised for fast expansion in the coming years, with projected growth to$3.19 billion by 2029, boasting a compound annual growth rate of 12.3%. This increase during the anticipated period can be correlated to a growing incidence of cancer, heightened awareness initiatives by the government, improved affordability of medical care, an uptick in expendable income within developing economies, and governmental efforts to raise cancer awareness. Key trends projected during this period encompass progress in next-generation sequencing (NGS) technology, the standardisation of MRD tests, the implementation of personalised MRD surveillance, advancements in liquid biopsy technologies, and therapies directed towards minimal residual disease.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21224&type=smp

Which Major Market Drivers Are Expected to Boost the Growth Potential of the Minimal Residual Disease Market?

The growth of the minimal residual disease (MRD) market is anticipated to be fueled by the escalating occurrence of cancer. Cancer, categorized by the unchecked proliferation and dissemination of atypical cells throughout the body, has seen a surge in incidence due to a number of factors. These include an increasing aged population, heightened exposure to environmental carcinogens, harmful lifestyle practices, and genetic predispositions. The surge in cancer cases amplifies the need for accurate MRD tests to identify leftover cancer cells, which facilitates prompt and tailored treatments. It consequently enhances the prediction of cancer recurrence and optimizes patient results. For instance, the National Cancer Institute (NCI), an American government agency, reported nearly 20 million new cancer cases and 9.7 million cancer-related fatalities worldwide in 2022. The institute further predicted that by 2040, these figures will reach 29.9 million new cancer cases and 15.3 million cancer-related deaths. Therefore, it’s evident that the rising incidence of cancer is a significant driver in the expansion of the MRD market.

Which Key Market Segments Comprise the Minimal Residual Disease Market and Drive Its Revenue Growth?

The minimal residual diseasemarket covered in this report is segmented –

1) By Detection Target: Lymphoma; Leukemia; Solid Tumors; Other Detection Targets

2) By Test Technique: Flow Cytometry; Polymerase Chain Reaction (PCR); Next Generation Sequencing (NGS); Other Test Techniques

3) By End-User: Banking, Financial Services, And Insurance (BFSI); Retail And E-Commerce; Hospitals; Diagnostic Laboratories; Research Institutions

Subsegments:

1) By Lymphoma: Hodgkin Lymphoma; Non-Hodgkin Lymphoma

2) By Leukemia: Acute Lymphoblastic Leukemia; Acute Myeloid Leukemia; Chronic Lymphocytic Leukemia; Chronic Myeloid Leukemia

3) By Solid Tumors: Breast Cancer; Lung Cancer; Colorectal Cancer; Prostate Cancer

4) By Other Detection Targets: Multiple Myeloma; Neuroblastoma; Sarcomas

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=21224&type=smp

Which Areas Are Leading Regions in the Minimal Residual Disease Market Expansion Across the Globe?

North America was the largest region in the minimal residual disease market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the minimal residual disease market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Are the Key Market Trends in theMinimal Residual Disease Market Over the Coming Years?

Key players in the minimal residual disease (MRD) market are investing in the creation of advanced in vitro diagnostic (IVD) test services. The goal is to offer personalized therapy options that improve patient results. IVD test services, which are lab-based diagnostic tools, can identify any residual cancer cells following treatment. This capability can foresee a relapse and refine treatment strategies. For example, in December 2022, Adaptive Biotechnologies Corporation, an American biotech firms, released its clonoSEQ Assay to locate minimal residual disease (MRD) in patients suffering from diffuse large B-cell lymphoma (DLBCL). The test examines circulating tumor DNA (ctDNA) in blood specimens, serving as a highly sensitive, non-intrusive method of tracking cancer development and spotting initial signs of relapse. The assay gives clinicians a more accurate picture of a patient’s disease load, enabling them to customize treatment plans. It’s the first MRD test for DLBCL to be approved for Medicare cover, ensuring its widespread use across all care plans and stages.

View the full report here:

https://www.thebusinessresearchcompany.com/report/minimal-residual-disease-global-market-report

How Is the Minimal Residual Disease Market Conceptually Defined?

Minimal residual disease (MRD) refers to the few cancer cells that persist in the body after treatment, despite clinical remission. Monitoring minimal residual disease (MRD) helps detect early signs of relapse, evaluate treatment effectiveness, and predict the risk of recurrence. This sensitive detection can guide tailored therapies to improve outcomes and reduce the likelihood of relapse.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21224

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

[KClientError] [REQ_ERR: OPERATION_TIMEDOUT] [KTrafficClient] Something is wrong.